News Archive

The results provide insight into which dose may be best for most patients.

The DCRI has received $44 million in funding to examine whether three immune modulators help prevent overactive immune response in moderate or severe cases of COVID-19.

The study includes both surveillance and exposure testing to reduce COVID-19 transmission and interviews with families to increase trust within communities.

The Antibacterial Resistance Leadership Group (ARLG) involves over 100 experts, generating over 155 papers and initiating 55+ studies with 21,000 participants at 130 sites in 12 countries.

More than twice as many patients saw changes in their patient-reported outcome measures compared with their traditional NYHA measures used by clinicians.

The program will evaluate testing results and other data to determine whether the intervention of providing self-administered COVID-19 tests helps to slow the rate of community transmission.

North Carolina models the way for national discussion and decisions on school re-openings during COVID-19 pandemic.

The HiLo study seeks to determine the optimal phosphate level for patients with chronic kidney disease.

The below is a republication of a story that featured DCRI’s Kanecia Zimmerman, MD, MPH, which appeared in Duke University School of Medicine’s digital publication, Magnify.

Over a third of patients with diabetes and heart disease were not taking any of the three therapies proven to prevent major adverse cardiovascular events.